Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
Armata Pharmaceuticals will present data at ISSSI 2026 showing that defined, controlled genetic diversity in its lead bacteriophage cocktail AP-SA02 may enhance killing of certain Staphylococcus aureus clinical isolates, including MRSA and MSSA. Genomic analyses identified a reproducible profile of genetic variants across clinical drug product lots, and the company deliberately maintains this diversity through controlled manufacturing as an intentional product attribute. The in vitro findings complement the Phase 2a diSArm study, in which 100% of evaluable AP-SA02-treated participants achieved a complete clinical response, and support the planned Phase 3 superiority study in complicated S.
Key figures
- Drug Name
- AP-SA02
- Phase Of Trial
- Phase 2a (diSArm); Phase 3 planned
- Conference
- ISSSI 2026, September 20-24, 2026, Banff, Alberta, Canada
- Phase3 timing
- second half of 2026
- Regulatory designations
- ["QIDP","Fast Track","Breakthrough Therapy"]
- Phase2a complete response rate
- 100% of evaluable participants achieved complete clinical response
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.